Answers are grounded in this paper and cite their sources.
Collaborations between patient organisations (POs) and the pharmaceutical industry can help identify and address the unmet needs of people living with a disease. In Alzheimer's disease (AD), the scale and complexity of the current unmet needs call for a broad and cross-sectoral collaboration, including people living with Alzheimer's (PLWA), their care partners and the wider research community.
No takes yet. Share an insight, caveat, or question.
Roeser et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: